TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
Ji-Yeon KimJaeyun JungKyoung-Mee KimJeeyun LeeYoung-Hyuck ImPublished in: Cancer medicine (2023)
Overall, we found each TP53 mutation to indicate different prognoses in patients with metastatic tumors undergoing chemotherapy and ICI treatment. Further validations, including a prospective cohort study or a functional study, would be particularly valuable in advancing the knowledge on this aspect and developing improved prognostic parameters.